LOS ANGELES, CA--(Marketwire - August 5, 2010) - Two weeks ago, Vyteris, Inc. (OTCBB: VYTR), the manufacturer of the first FDA-approved active patch transdermal drug delivery system announced the appointment of four new members to its Scientific Advisory Board. The news went mostly unnoticed, but it could point to some significant catalysts and developments for a company that recently found itself on the ropes.